Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: A nonrandomised controlled trial with magnetic resonance spectroscopy

CNS Drugs

Volumn 20, Issue 10, 2006, Pages 867-877

  Modrego, Pedro J ^a,d   Pina, Miguel A ^b   Fayed, Nicolás ^c   Díaz, Marcos ^b  

^a Hospital de Alcañiz   (Spain)

^b HOSPITAL OBISPO POLANCO   (Spain)

^c HOSPITAL QUIRÓN   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; INOSITOL; N ACETYLASPARTIC ACID; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOTRANSFORMATION; BRAIN; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES;

EID: 33749245441     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620100-00006     Document Type: Article

References (35)

1. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001; 56: 592-8
2. Jung R, Yeo R, Chiulli S, et al. Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. Neuroreport 2000; 10: 3327-31
3. Ross B, Bluml S, Cowan R, et al. In vivo magnetic resonance spectroscopy: the biophysical basis of dementia. Biophys Chem 1997; 68: 161-72
4. Pfefferbaum A, Adalsteinsson E, Spielman D, et al. In vivo brain concentration of N-acetyl compounds, creatine and choline in Alzheimer's disease. Arch Gen Psychiatry 1999; 56: 185-92
5. Meyerhoff D, MacKay S, Constans J, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopy imaging. Ann Neurol 1994; 36: 40-7
6. 1H MR spectroscopy in common dementias. Neurology 2004; 63: 1393-8
7. Waldman AD, Rai GS. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study. Neuroradiology 2003; 45: 507-12
8. Chantal S, Labelle M, Bouchard RW, et al. Correlation of regional proton magnetic resonance spectroscopy metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 2002; 59: 955-62
9. Satlin A, Bodick N, Offen W, et al. Brain proton magnetic resonance spectroscopy (1-H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 1997; 154: 1459-61
10. Krishnan RR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer disease. Am J Psychiatry 2003; 160: 2003-11
11. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67
12. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8
13. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; (2): CD001191
14. Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am Geriatr Psychiatry 2004; 12: 358-69
15. Grossberg G, Irwin P, Satlin A, et al. Rivastigmine in Alzheimer disease: efficacy over two years [published erratum appears in Am J Geriatr Psychiatry 2004; 12 (6): 679]. Am J Geriatr Psychiatry 2004; 12: 420-31
16. The American Psychiatric Association. Diagnostical and statistical manual of mental disorders. 4th ed. Barcelona: Masson, 1995
17. McKhan G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
18. Lobo A, Ezquerra J, Gómez Burgada F, et al. El mini-examen cognoscitivo: Un test sencillo y práctico para detectar alteraciones intelectuales en pacientes médicos. Actas Luso Esp Neurol Psichiatr Cienc Afines 1979; 3: 198-202
19. Teunisse S, Derix MM, Crever H. IDDD: assessing the severity of dementia: patient and caregiver. Arch Neurol 1991; 48: 274-7
20. Christiansen P, Schlosser A, Henriksen O. Reduced N-acetylas-partate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn Reson Imaging 1995; 13: 457-62
21. Schuff N, Amend DL, Meyerhoff DJ, et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998; 207: 91-102
22. Schuff N, Capizzano A, Du AT, et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002; 58: 928-35
23. Miller BL, Moats RA, Shonk T, et al. Alzheimer's disease: depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 1993; 187: 433-7
24. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65-72
25. Rai GS, McConnel JR, Waldman A, et al. Brain proton spectroscopy in dementia: an aid to clinical diagnosis. Lancet 1999; 353: 1063-4
26. Jack CR, Slomkowski M, Gracon S, et al. MRI as biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60: 253-60
27. Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162: 676-82
28. Marjanska M, Curran GL, Wengenack TM, et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 2005; 102: 11906-10
29. Frederick B, Satlin A, Wald LL, et al. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry 2002; 10: 81-8
30. Nobili F, Koulibaly M, Vitali P, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002; 43: 983-90
31. Rombouts SA, Barkhof F, Van Meel CS, et al. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73: 665-71
32. Kaasinen V, Nagren K, Jarvenpaa T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002; 22: 615-20
33. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 315-9
34. Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomography study. Arch Neurol 2005; 62: 721-8
35. Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 2006 Feb; 113 (2): 205-18. Epub 2005 Jul 29